

TUBERCULOSTATIC ACTIVITY OF RIFABUTIN (MYCOBUTIN) AND ITS CLINICAL EFFICACY IN PATIENTS WITH DESTRUCTIVE RESISTANT PULMONARY TUBERCULOSIS

I. B. Byalyk, L. M. Tsygankova, Zh. E. Vyalykh
Summary

It has been proved the higher bacteriostatic activity and clinical efficacy of rifabutin in comparison with rifampicin. The partial cross resistance of mycobacterium tuberculosis to rifampicin and rifabutin (almost in 90 % of cases) was registered. During the treatment with rifabutin in combination with other antituberculosis medicines the rate of sputum abacilation was 23 % higher, and the rate of partial or complete cavern regression — 1,3—1,5 months faster, than in those regimens without rifabutin.